Stage III Kidney Wilms Tumor Clinical Trial
Official title:
A Genome-Wide Association Study in Wilms Tumor
This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.
PRIMARY OBJECTIVES:
I. To use a genome-wide association analysis to identify novel genetic variants that confer
susceptibility to Wilms tumor.
II. To improve our understanding of the genetic architecture and etiology of Wilms tumor.
III. To facilitate the identification of genetic markers that are associated with an
increased risk of developing of Wilms tumor and/or those at risk of aggressive disease,
relapse, additional tumors and/or cancer in their offspring.
OUTLINE:
Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time
polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA).
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00352534 -
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
|
Phase 3 | |
| Recruiting |
NCT04322318 -
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
|
Phase 2 | |
| Active, not recruiting |
NCT00945009 -
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
|
Phase 3 | |
| Active, not recruiting |
NCT00379340 -
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
|
Phase 3 |